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Abstract  
Most of the neurodegenerative diseases that afflict humans manifest with the 
intraneuronal accumulation of toxic proteins which are aggregate-prone. Extensive data 
in cell and neuronal models support the concept that such proteins, like mutant 
huntingtin or alpha-synuclein, are substrates for macroautophagy (hereafter 
autophagy). Furthermore, autophagy-inducing compounds lower the levels of such 
proteins and ameliorate their toxicity in diverse animal models of neurodegenerative 
diseases. However, most of these compounds also have autophagy-independent effects 
and it is important to understand if similar benefits are seen with genetic strategies that 
upregulate autophagy, as this strengthens the validity of this strategy in such disease. 
Here we review studies in vertebrate models using genetic manipulations of core 
autophagy genes and describe how these improve pathology and neurodegeneration, 
this supporting the validity of autophagy upregulation as a target for certain 
neurodegenerative diseases.  
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Clearance of aggregate-prone proteins by autophagy 
Many neurodegenerative diseases such as Alzheimer’s disease (AD), Huntington’s diseases 
(HD), Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB) share the similar 
neuropathology of mutant protein misfolding and aggregation in the brain (Bancher et al., 
1989; DiFiglia et al., 1997; Spillantini et al., 1998). In cells, mutant proteins associated with 
neurodegenerative diseases can form various oligomeric species and insoluble aggregates. 
We now know that many of the mutations confer new, toxic, gain-of-function properties on 
the proteins that eventually cause the death of specific neuronal populations in these diseases 
(Arrasate et al., 2004; Ashkenazi et al., 2017; DiFiglia et al., 1997). Thus, reduction in the 
levels of all species (soluble and insoluble) of the misfolded proteins can reduce the toxic 
burden in cells and prevent neuronal death (Berger et al., 2006; Ravikumar et al., 2002).  
The ubiquitin-proteasome system and macroautophagy (hereafter autophagy) are the main 
degradative pathways within cells. Autophagy is an efficient process that clears cytoplasmic 
oligomeric species of the toxic proteins that are not accessible to the proteasome 
(Ciechanover and Kwon, 2015; Rubinsztein, 2006). Overall, autophagy induction shows 
beneficial effects by decreasing both the soluble and the insoluble forms of the misfolded 
proteins. Autophagy may also be able to reduce the levels of intraneuronal aggregates in 
some diseases, like spinocerebellar ataxia type 3, by enabling the removal of intracytoplasmic 
species which are in equilibrium with the mutant protein in the nucleus. Several molecules 
have been reported to induce autophagy and show beneficial effects in animal models of 
neurodegenerative diseases (Menzies et al., 2017; Rubinsztein et al., 2012). However, most of 
these compounds also have autophagy-independent effects and it is important to understand if 
similar benefits are seen with genetic strategies that upregulate autophagy, as this strengthen 
the validity of this strategy in such disease.  
There is accumulating genetic support for the benefits of autophagy induction in vivo in 
models of neurodegeneration using mammalian autophagy proteins (ATG) that are involved 
in the synthesis of autophagosomes. In this review, we will briefly summarize small and non-
small molecule inducers of autophagy and focus on autophagy genes that induce autophagy 
and reduce toxicity in animal models of AD, HD, and PD.    
Key autophagy genes for autophagosome synthesis 
The first morphologically recognisable structure in autophagy is a double-layered, cup-
shaped membrane structure called a phagophore that elongates and engulfs cytoplasmic cargo 
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such as aggregate-prone proteins. After the edges of the phagophores are closed to form 
vesicular autophagosomes, these traffic to and fuse with lysosomes and thereby form 
autolysosomes, in which the luminal content is degraded by lysosomal enzymes (Mizushima 
et al., 2008). There are several key ATG that regulate this process (Figure 1).  
Upon autophagy induction by nutrient deprivation (an evolutionary conserved autophagy 
stimulus), the class III VPS34 is recruited to nascent phagophore membranes. In a complex 
with ATG6 (beclin 1), VPS15, and ATG14, class III VPS34 generates phosphatidylinositol 3-
phosphate (PI3P) (Tassa et al., 2003). PI3P on autophagosomal precursor membranes recruits 
PI3P effectors such as WD repeat domain phosphoinositide-interacting protein 2 (WIPI2). 
This enables WIPI2 to interact with other downstream autophagy effectors, such as 
ATG16L1, which regulate the formation of autophagosomes (Ashkenazi et al., 2017; Dooley 
et al., 2014; Vicinanza et al., 2015).  
ATG16L1 acts in a complex with ATG12 and ATG5. ATG12, an ubiquitin like molecule, is 
conjugated to ATG5 by the E1- and E2-like enzymes ATG7 and ATG10, respectively. 
Subsequently, ATG12-ATG5 binds non-covalently to ATG16L1. The interaction of the 
ATG12-ATG5-ATG16L1 complex with pre-autophagosomal membranes assist in the 
recruitment of members of the Atg8 family, like LC3, another ubiquitin-like protein. This is 
achieved via the conjugation of LC3-I to phosphatidylethanolamine which thereby generates 
lipidated LC3B-II on autophagosomal membranes. This reaction is governed by ATG7, 
ATG3, and ATG12-ATG5-ATG16L1, acting as E1-, E2-, and E3-like enzymes, respectively. 
The Atg8/LC3 family are thought to promote phagopore elongation and closure to generate a 
complete autophagosome vesicle (Bento et al., 2016). Specific knock-out of Atg5 and Atg7 in 
neurons causes accumulation of neuronal aggregates (Hara et al., 2006; Komatsu et al., 
2006), emphasising the crucial importance of autophagy in maintaining normal neuronal 
homeostasis. 
Main regulatory pathways of autophagosome synthesis 
In normal physiological conditions, autophagosome synthesis occurs at a basal level, but the 
autophagy flux can further increased upon nutrient deprivation. This is partially governed by 
inhibition of mammalian target of rapamycin (mTOR), a serine/threonine kinase, which 
interacts with partner proteins in a larger complex termed the mTOR complex 1 (mTORC1). 
mTORC1 and AMP-dependent protein kinase (AMPK) sense intracellular levels of energy 
(e.g. AMP/ATP ratio), nutrients, and growth factors, and control the activity of the 
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mammalian Atg1 homologues UNC-51-like kinase (ULK1/2), a serine/threonine-protein 
kinase (Kim et al., 2011). ULK1/2 resides in a complex with ATG101, ATG13, and focal 
adhesion kinase family interacting protein of 200 kD (FIP200). Activation of the ULK 
complex regulates the efficient recruitment of the class III VPS34 complex to pre-
autophagosomal membranes to initiate autophagosome synthesis, as described above. A chain 
of phosphorylation events controls the activation of the ULK complex. In this regard, AMPK 
is a positive regulator of the ULK complex, while mTORC1 is a negative regulator (Ganley 
et al., 2009; Laplante and Sabatini, 2012). Neuronal knockouts of Fip200 and Ulk1/2 in mice 
cause progressive degeneration in different parts of the brain (Joo et al., 2016; Liang et al., 
2010). Another interaction that regulates autophagy at the level of the VPS34 complex is via 
B-cell lymphoma 2 (BCL2). BCL2 inhibits autophagy through an interaction with the BH3 
domain of the beclin 1, and this association is disrupted by nutrient deprivation-induced 
autophagy (He et al., 2012).        
Autophagosome synthesis is also transcriptionally regulated. Under normal physiological 
conditions, mTORC1 phosphorylates transcription factor EB (TFEB), which keeps TFEB in 
the cytosol (Settembre et al., 2012). Under nutrient-deprived conditions where mTORC1 is 
inactive, TFEB is no longer phosphorylated and translocates to the nucleus, where it initiates 
transcription of many genes directly involved in the biogenesis of lysosomes and the 
synthesis of autophagosomes (Roczniak-Ferguson et al., 2012; Settembre et al., 2011).   
Small molecule inducers of autophagy in animal models of neurodegeneration 
Several small molecule inducers of autophagy affect upstream regulatory pathways of 
autophagosome synthesis, such as mTOR. Rapamycin and other rapalogs are non-ATP 
competitive inhibitors of mTOR, with selectivity towards mTORC1 (Kim and Guan, 2015). 
These compounds are autophagy inducers and have beneficial effects in several animal 
models of AD, PD, frontotemporal dementia (FTD), prion diseases (PrP), and HD (Cortes et 
al., 2012; Jiang et al., 2014; Menzies et al., 2010; Ozcelik et al., 2013; Ravikumar et al., 
2004; Sarkar et al., 2009; Spilman et al., 2010; Wang et al., 2012). However, there is a 
growing list of molecules that act on targets independent of mTOR. One such target is 
AMPK, which recently was discovered to be the target of another potent autophagy inducer, 
trehalose, a molecule that has been well-studied in vivo (DeBosch et al., 2016). This 
disaccharide induces autophagy and ameliorates toxicity in animal models of AD, FTD, PD, 
HD, spinocerebellar ataxia type 17 (SCA17), amyotrophic lateral sclerosis (ALS), and 
oculopharyngeal muscular dystrophy (OPMD) (Aguib et al., 2009; Castillo et al., 2013; Chen 
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et al., 2015; Davies et al., 2006; Li et al., 2015; Rodriguez-Navarro et al., 2010; Schaeffer and 
Goedert, 2012; Tanaka et al., 2004; Tanji et al., 2015). Other AMPK activators, such as 
metformin (Berthier et al., 2016; Ma et al., 2007; Son et al., 2016) and nilotinib (Hebron et 
al., 2014; Lonskaya et al., 2015; Yu et al., 2013), also show beneficial effects in models of 
neurodegeneration.  
Another group of compounds act on cyclic AMP (cAMP) and inositol triphosphate (IP3) 
pathways, independently of mTOR (Williams et al., 2008). While IP3 impacts many 
processes, it also negatively regulates autophagy. Lithium administration prevents inositol 
recycling and reduces IP3 levels, which induces autophagy, and has been shown to be 
beneficial in an animal model of AD (Zhang et al., 2011). Additional compounds that seem to 
act on this cAMP-IP3 autophagy pathway are rilmenidine, minoxidil, clonidine, and verapamil 
(Rose et al., 2010; Williams et al., 2008). It should be noted that these compounds may have 
other targets that are not autophagy related.  Rilmenidine was recently tested in an open-label 
study to assess the feasibility and tolerability of the drug for HD patients (Underwood et al., 
2017). 
Gene therapy approaches using core autophagy genes in models of neurodegenerative 
disease 
While studies of the aforementioned compounds suggest that autophagy upregulation is 
beneficial in many animal models of neurodegenerative disease, these molecules and their 
targets may also impact pathways distinct from autophagy. Thus, genetic studies 
manipulating autophagy proteins allow an alternative and potentially more specific way to 
validate autophagy as a target for some of these conditions. Virally-mediated gene therapy 
using beclin 1 (Becn1) has been the most frequently used strategy for such objectives and  has 
benefits in animal models of neurodegenerative disease such as AD (Pickford et al., 2008; 
Rocchi et al., 2017), PD (Spencer et al., 2009), and polyglutamine diseases (Nascimento-
Ferreira et al., 2011). Additionally, both ATG5 and ATG7 have been reported to have 
neuroprotective properties in in vivo models of neurodegeneration (Crews et al., 2010; Lopez 
et al., 2017). In the following section we will elaborate on some recent studies which have 
used core autophagy genes to rescue animal models of neurodegenerative disease. 
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Beclin 1 
Alzheimer’s disease 
Pickford and co-workers showed neurobeneficial effects of beclin 1 expression in a mouse 
model of AD (Pickford et al., 2008). The authors used the transgenic T41 mice expressing 
amyloid precursor protein (APP) with both the Swedish (K670N/M671L) and the London 
(V717I) mutations, which develop amyloid plaques in the frontal cortex, hippocampus, 
thalamus, and the olfactory region associated with an age-dependent decline in learning and 
memory skills (Rockenstein et al., 2001). Crossing T41 APP heterozygous mice with 
Becn1+/- mice (Becn1-/- is prenatal lethal) caused increased accumulation of amyloid-β (Aβ) 
immunoreactivity in the hippocampus and frontoparietal cortex of 9-month-old mice 
compared to age-matched T41 APP+ mice. The accumulation of Aβ was further confirmed by 
ELISA of formic acid-extracted Aβ species, which was inversely correlated with the levels of 
beclin 1 in the mice. Electron microscopy analysis of neurons from 5-months-old mice 
revealed abnormally enlarged lysosomes containing electron dense material, and western 
blotting of cortical tissue from 16-months-old APP+ x Becn+/--crossed mice showed reduced 
LC3II/I conversion ratio by western blotting. Additionally, in the prefrontal cortex of 9-
months-old APP+ x Becn+/- mice, the authors observed increased numbers of activated CD68+ 
microglia, the innate immune cells of the brain, which was associated with loss of 
synaptodendritic integrity, an early indicator of ongoing neurodegeneration. Conversely, 
expressing beclin 1 via lentiviral transduction in hippocampus and cortex of APP+ mice 
significantly reduced accumulation of Aβ and thioflavin-positive aggregates, when compared 
to the contralateral side of the brain only receiving GFP control lentivirus. 
These findings have been expanded by a recent study using an elegant new mouse model 
expressing a knock-in mutant F121A in Becn1, which prevents BCL2 binding to the BH3 
domain of beclin 1 and consequently decreases its inhibitory effect on autophagy (Rocchi et 
al., 2017). These mice have hyperactive autophagy flux indicated by increased LC3-II levels 
and reduced p62 levels. Injecting the lysosomal inhibitor chloroquine to the mice even further 
increased the LC3-II levels, underscoring an increased autophagy flux in the Becn1F121A mice. 
These mice were crossed with 5xFAD transgenic AD mice, which express 5 familial 
mutations in human APP and presenilin (PS1) genes, which causes amyloid plaques at an age 
of 2 months and cognitive decline after 6 months (Oakley et al., 2006). The BeclinF121A mice 
crossed with 5xFAD mice have reduced accumulation of soluble as well as insoluble Aβ42, 
reduced thioflavin-positive aggregates in the cortex, had longer survival rates, and performed 
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significantly better in the Morris water maze than the 5xFAD age-matched mice. Thus, 
promoting autophagy via beclin 1 is neuroprotective in various models of AD. 
Parkinson’s disease 
Beclin 1 also is protective in models of PD (Spencer et al., 2009), for example in transgenic 
mice expressing α-synuclein under the neuronal specific PDGF-β  promoter. These mice 
experience neuronal accumulation of aggregated α-synuclein, loss of dopaminergic neurons, 
and lysosomal abnormalities, which is associated with behavioural defects (Masliah et al., 
2000). In vivo lentiviral expression of beclin 1 in temporal cortex and hippocampus of the α-
synuclein transgenic mice increased LC3 immunoreactivity in these areas, which was 
associated with lowering of the neuronal α-synuclein burden. In beclin 1 expressing mice α-
synuclein were more frequently found in vesicular structures in neurons indicative of 
autophagosomal processing of the pathogenic protein. This was accompanied with 
preservation of the neuronal network, indicated by sustained immunoreactivity for 
synaptophysin and MAP2 in the brain area near the injection sites, when compared to control 
injected mice. 
Polyglutamine diseases 
Beclin 1 overexpression also has beneficial consequences in a model of Machado-Joseph 
disease (MJD)/SCA3, an autosomal dominant disease caused by a polyglutamine (polyQ) 
expansion encoded by an elongated CAG trinucleotide repeat mutation in the coding region 
of the ataxin-3 gene (Kawaguchi et al., 1994). Post-mortem brain tissues and fibroblasts from 
MJD patients have lower levels of beclin 1 (Ashkenazi et al., 2017; Nascimento-Ferreira et 
al., 2013; Sittler et al., 2017). The polyQ stretch in wild-type ataxin-3 allows it to bind and 
deubiquitinate beclin 1 (Ashkenazi et al., 2017). Thus, ataxin-3 can protect beclin 1 from 
proteasome-mediated degradation and thereby promote autophagy. Expansion of the polyQ 
tract in ataxin-3 decreases its deubiquitinase activity toward beclin-1 in vitro, which 
destabilizes beclin 1 levels (Ashkenazi et al., 2017). Accordingly, lentiviral beclin 1 
overexpression attenuated mutant ataxin-3-induced pathology in the striatum of a rat model 
of SCA3 (Nascimento-Ferreira et al., 2011). The beclin 1 expression significantly reduced the 
number of mutant ataxin-3-positive aggregates. Similar benefits were observed with lentiviral 
overexpression of beclin 1 in a transgenic mouse model of this disease (Nascimento-Ferreira 
et al., 2013). 
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ATG5 
Alzheimer’s disease 
The rare p.A153T variant of the microtubule associated protein tau (MAPT) is associated 
with increased risk of FTD and AD (Coppola et al., 2012). In order to study this tau variant in 
vivo, an experimental zebrafish model was generated expressing wild-type tau or mutant 
tauA153T both coupled to the photoactivatable fluorophore Dendra (Lopez et al., 2017). The 
tauA152T zebrafish showed morphological abnormalities in the spinal cord, reduced motor 
neuron numbers, and accordingly had impaired escape responses. Additionally, the mutant 
fish had increased levels of pathogenic hyperphosphorylated tau, which was associated with 
reduced degradation kinetics of the tau protein. While the autophagy flux was unaffected in 
the zebrafish with the tauA153T variant, proteasomal clearance was impaired, indicated by 
reduced degradation of the proteasome-specific substrate UbG76V-GFP (Dantuma et al., 
2000). As tau is known to be a substrate for both proteasome and autophagy degradation (Lee 
et al., 2013), we tested whether promoting the autophagy pathway could reverse the 
accumulation of tau and morphological defects observed in the tauA153T zebrafish. Both 
chemically and genetic promotion of autophagy rescued the pathology observed in the 
zebrafish. The latter was accomplished by transient expression of the autophagy gene Atg5, 
which upregulated autophagy and ameliorated the abnormal morphology of the zebrafish 
carrying the tauA153T variant. 
ATG7 
Brain homogenates from post-mortem patients with dementia with Lewy bodies (DLB) or 
from mice overexpressing human wild-type α-synuclein revealed downregulation of ATG7 
and upregulation of the negative autophagy regulator mTOR (Crews et al., 2010). 
Interestingly, lentiviral-mediated overexpression of ATG7 in the cortex and the hippocampus 
of α-synuclein transgenic mice significantly reduced the α-synuclein burden while preserving 
the neuronal network indicated by MAP2 staining. 
Other autophagy related genes  
Expression of upstream activators of autophagy has also shown to be neuroprotective in 
several models of neurodegenerative disorders. Viral overexpression of TFEB in the striatum 
of HD mice (HDQ175/Q7) promoted autophagy and reduced levels of the disease causing 
protein, mutant huntingtin (Vodicka et al., 2016). Similarly, viral-mediated expression of 
TFEB was beneficial in a rat model of PD expressing human α-synuclein, causing a 
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significant reduction in the α-synuclein load, accompanied by preservation of dopaminergic 
neurons (Decressac et al., 2013).  
In conclusion, genetic manipulation of both core autophagy genes but also close regulators of 
the autophagy pathway is neuroprotective in various in vivo models of neurodegeneration.  
These studies provide strong support along with the existing literature on chemical 
stimulators of autophagy, that specific upregulation of this pathway is beneficial in various 
models of neurodegenerative diseases. These genetic studies also allow assessment of the 
safety of this strategy – e.g. no side effects were reported in the Becn1F121A mice and ATG5 
transgenic mice have increased lifespans and antiageing phenotypes (Pyo et al., 2013). In 
addition, genetic strategies may be promising avenues to pursue for human therapeutics. For 
example, the autophagy-inducing beclin 1 peptide strategy described by Levine and 
colleagues (Shoji-Kawata et al., 2013) suggests approaches distinct from conventional small 
molecules that may have utility in diseases where autophagy upregulation may be 
advantageous. Finally, it is important to bear in mind that while induction of autophagosome 
biogenesis may be beneficial in many neurodegenderative diseases, it may not be effective 
and could possibly be deleterious when autophagy flux is impaired after autophagosomes are 
formed, for example by mutations affecting lysosomal activity. Thus, understanding the 
molecular basis of disease will be an important adjunct to this and many other therapeutic 
approaches. 
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Figure legend 
Figure 1. Schematic overview of selected core autophagy proteins and their involvement 
in autophagy. The formation of an autophagosome is initiated by activation of the ULK 
complex (ULK1/2, ATG13, and FIP200) which subsequently 1) recruits the beclin 1, VPS34, 
VPS15 and ATG14L complex. VPS34 generates phosphatidylinositol 3-phosphate (PI3P) at 
the phagophore membrane. 2) The levels of beclin 1 are regulated by ubiquitination via E3 
ligases which target it for 3) proteasomal degradation. 2) Conversely, deubiquitinases (DUB), 
e.g. Ataxin-3, deubiquitinates beclin 1 and thereby enables it to associate with VPS34 
complexes and to induce autophagy. 4) PI3P facilitates recruitment of WIPI2 to the 
phagophore, which subsequently interacts with the ATG16L1/ATG5-ATG12 complex. 5) 
Pro-LC3 is cleaved by ATG4 to form cytosolic LC3-I, which interacts with ATG7 and 
subsequently ATG3. 6) ATG7 acts as an E1–like enzyme and couples LC3-I to the E2-like 
enzyme ATG3. This enables the E3-like complex of ATG16L1/ATG5-ATG12 to conjugate 
the ubiquitin-like LC3-I to phosphatidylethanolamine in phagophore membranes, thereby 
forming lipidated LC3-II. 7) The recruitment to autophagosomes of some cytosolic cargoes, 
like aggregate-prone proteins, is enhanced by autophagy receptors e.g. SQSTM1/p62, which 
link these substrates to LC3-II. 8) Eventually, the phagophore membrane closes to form a 
vesicular autophagosome which 9) fuses with low-pH lysosomes. Degradative enzymes from 
the lysosome will degrade the luminal content of autophagsomes. 
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